文献速递甲状腺疾病垂体与肾上腺疾病

苯丁酸治疗一例MCT8缺陷男童:甲状腺功能检查改善及可能的肝毒性

Phenylbutyrate Treatment in a Boy With MCT8 Deficiency: Improvement of Thyroid Function Tests and Possible Hepatotoxicity.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文报告一例由新型MCT8错义突变c.703G>T(p.V235L)所致MCT8缺陷男童,接受与尿素循环障碍获批剂量相当的苯丁酸治疗13个月,促甲状腺激素和T3显著下降、fT4升高,体重z评分稳定,粗大运动技能轻度改善,但肝酶升高和尿苯乙酸蓄积导致治疗中断和剂量调整。体外实验证实该突变致病性,苯丁酸虽增加突变蛋白表达但未恢复T3转运。

要点

  • 苯丁酸治疗13个月使该MCT8缺陷男童促甲状腺激素和T3显著下降、fT4升高。
  • 治疗期间体重z评分保持稳定,粗大运动发育年龄从4个月轻度增至6个月。
  • 肝酶升高和尿苯乙酸蓄积导致治疗中断和剂量调整,可能为剂量限制性肝毒性。

核心结论

  • 在一例MCT8缺陷的临床苯丁酸治疗尝试中,观察到甲状腺激素功能检查显著改善、体重稳定趋势和轻度神经发育改善。
  • 苯丁酸的肝毒性可能是MCT8缺陷中的限制因素,需要进一步研究。

研究设计与样本

  • 单例MCT8缺陷男童(新型MCT8错义突变c.703G>T,p.V235L)的苯丁酸治疗临床尝试,剂量相当于获批用于尿素循环障碍的剂量,治疗期13个月。
  • 体外分析使用MDCK1细胞评估MCT8 p.V235L的致病性及苯丁酸对突变蛋白表达和T3转运的影响。

主要发现

  • 治疗13个月期间,苯丁酸使升高的促甲状腺激素和T3血清浓度显著下降,同时fT4升高。
  • 该幼儿的体重z评分在治疗期间保持显著稳定。
  • BSID-III神经发育评估显示粗大运动技能从发育年龄4个月轻度增至6个月。
  • 肝酶血清活性升高和尿苯乙酸蓄积导致治疗中断和剂量调整。
  • MDCK1细胞体外分析证实MCT8 p.V235L的致病性;苯丁酸增加突变蛋白表达,但未恢复T3转运,提示苯丁酸对甲状腺功能检查的作用独立于恢复MCT8活性。

局限性

  • 苯丁酸的肝毒性可能是MCT8缺陷中的限制因素,需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Monocarboxylate transporter 8 (MCT8) deficiency is a rare X-chromosomal inherited disease leading to severe cognitive impairment, muscular hypotonia, and symptoms of peripheral thyrotoxicosis. Experimental approaches aiming to functionally rescue mutant MCT8 activity by the chemical chaperone phenylbutyrate (PB) demonstrated promising effects in vitro for several MCT8 missense mutations. OBJECTIVE: The objective was to evaluate biochemical and clinical effects of PB in doses equivalent to those approved for the treatment of urea cycle disorders in a boy with MCT8 deficiency due to a novel MCT8 missense mutation c.703G>T (p.V235L). RESULTS: During a treatment period of 13 months, PB led to a significant decrease of elevated thyrotropin and triiodothyronine (T3) serum concentrations, while free thyroxine (fT4) increased. The weight z-score of the toddler remained remarkably stable during the treatment period. Neurodevelopmental assessments (BSID-III) revealed a slight increase of gross motor skills from developmental age 4 to 6 months. However, increasing liver enzyme serum activities and accumulation of phenylacetate in urine led to treatment interruptions and dose alterations. In vitro analyses in MDCK1 cells confirmed the pathogenicity of MCT8 p.V235L. However, while PB increased expression of the mutant protein, it did not rescue T3 transport, suggesting a PB effect on thyroid function tests independent of restoring MCT8 activity. CONCLUSION: In a clinical attempt of PB treatment in MCT8 deficiency we observed a significant improvement of thyroid hormone function tests, tendencies toward body weight stabilization and slight neurodevelopmental improvement. Hepatotoxicity of PB may be a limiting factor in MCT8 deficiency and requires further investigation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schreiner F, Vollbach H, Sonntag N, et al. Phenylbutyrate Treatment in a Boy With MCT8 Deficiency: Improvement of Thyroid Function Tests and Possible Hepatotoxicity. J Clin Endocrinol Metab. 2025. PMID: 38781537. doi:10.1210/clinem/dgae356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。